Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 6/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.62 |
| ▸ | DRD3 | P35462 | 2/20 | 0.62 |
| ▸ | HTR2B | P41595 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | MLNR | O43193 | 1/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6261397 | 0.94 | ALOX15 (0.74) | ALDH1A1ALOX15MEN1KMT2AKCNH2 | |
| SCHEMBL8556384 | 0.94 | MEN1 (0.60) | ALDH1A1ALOX15MEN1KMT2AKCNH2 | |
| SCHEMBL26007622 | 0.94 | ALDH1A1 (0.58) | ALDH1A1ALOX15MEN1KMT2AKCNH2 | |
| Pyrrocaine SCHEMBL25718 | 0.93 | MEN1 (0.70) | ALDH1A1ALOX15MEN1KMT2AKCNH2 | |
| SCHEMBL2096761 | 0.92 | MEN1 (0.73) | ALDH1A1MEN1KMT2AKCNH2ADRB1 | |
| Pyrrocaine SCHEMBL10757216 | 0.92 | MEN1 (0.68) | ALDH1A1ALOX15MEN1KMT2AKCNH2 | |
| Pincainide SCHEMBL2110148 | 0.92 | MEN1 (0.73) | ALDH1A1MEN1KMT2AKCNH2ADRB1 | |
| SCHEMBL22407740 | 0.92 | MEN1 (0.73) | ALDH1A1MEN1KMT2AKCNH2ADRB1 | |
| Pyrrocaine SCHEMBL1651381 | 0.91 | MEN1 (0.67) | ALDH1A1ALOX15MEN1KMT2AKCNH2 | |
| SCHEMBL12598795 | 0.90 | CYP3A4 (0.70) | ALDH1A1ALOX15MEN1KMT2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110223213-A1 | HIGHLY PURE RANOLAZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-09-15 | — | — | US | claimed |
| EP-2356097-A2 | HIGHLY PURE RANOLAZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Actavis Group PTC ehf. (IS) | 2011-08-17 | — | — | EP | claimed |
| WO-2010043976-A2 | HIGHLY PURE RANOLAZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2010-04-22 | — | — | WO | claimed |
| EP-3782992-A1 | NOVEL PROCESS FOR THE PREPARATION OF RANOLAZINE | UNICHEM LABORATORIES LIMITED (IN) | 2021-02-24 | — | — | EP | disclosed |
| US-10266507-B2 | Process for the preparation of ranolazine | UNICHEM LABORATORIES LIMITED (IN) | 2019-04-23 | — | — | US | disclosed |
| US-20180044307-A1 | NOVEL PROCESS FOR THE PREPARATION OF RANOLAZINE | UNICHEM LABORATORIES LIMITED (IN) | 2018-02-15 | — | — | US | disclosed |
| WO-2016142819-A2 | NOVEL PROCESS FOR THE PREPARATION OF RANOLAZINE | UNICHEM LABORATORIES LIMITED (IN) | 2016-09-15 | — | — | WO | disclosed |
| US-8541578-B2 | Process for the production of n-(2,6-dimethyl-phenyl)-2-piperazin-1-yl-acetamide | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-09-24 | — | — | US | disclosed |
| US-8541578-B2 | Process for the production of n-(2,6-dimethyl-phenyl)-2-piperazin-1-yl-acetamide | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20110223213-A1 | HIGHLY PURE RANOLAZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-09-15 | — | — | US | disclosed |
| US-20110223213-A1 | HIGHLY PURE RANOLAZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-09-15 | — | — | US | disclosed |
| EP-2356097-A2 | HIGHLY PURE RANOLAZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Actavis Group PTC ehf. (IS) | 2011-08-17 | — | — | EP | disclosed |
| US-20110151258-A1 | PREPARATION OF RANOLAZINE | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-06-23 | — | — | US | disclosed |
| WO-2010043976-A2 | HIGHLY PURE RANOLAZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010043976-A2 | HIGHLY PURE RANOLAZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010025370-A2 | PREPARATION OF RANOLAZINE | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-04 | — | — | WO | disclosed |
| EP-1517900-B1 | PROCESS FOR THE PRODUCTION OF N-(2,6-DIMETHYL-PHENYL)-2-PIPERAZIN-1-YL-ACETAMIDE | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110223213-A1 | HIGHLY PURE RANOLAZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | REN, ADRB3, RAN | ALDH1A1 2045/4885ALOX15 2337/4885MEN1 4060/4885 |
| US-10266507-B2 | Process for the preparation of ranolazine | SCN7A, SCN5A, CYP3A7 | ALDH1A1 410/4885ALOX15 1542/4885MEN1 3518/4885 |
| US-20180044307-A1 | NOVEL PROCESS FOR THE PREPARATION OF RANOLAZINE | SCN7A, CYP3A7, SCN5A | ALDH1A1 473/4885ALOX15 1566/4885MEN1 3503/4885 |
| US-20110151258-A1 | PREPARATION OF RANOLAZINE | RANBP1, RAN, ACHE | ALDH1A1 949/4885ALOX15 1121/4885MEN1 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.